top of page

Free Biopharma Daily Stock Updates - 10/12/21

$XBI $124.61 +0.44%

 

Covid Updates

$MRNA +2.0% Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna’s COVID-19 Vaccine for Low Income Countries in First Half of 2022 source


$INO +1.8% INOVIO Announces Online Preprint Publication of Homologous Boosting Data for its COVID-19 DNA Vaccine Candidate, INO-4800 source


$ARCT +3.0% Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern source


$IFRX +5.1% 10-2021-InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19 source



Pipeline Updates

$CRSP +1.9% CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies source


$EYPT +6.4% EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ® CALM Registry Study at American Society of Retina Specialists (ASRS) 39th Annual Meeting source


$GRPH +3.6% Graphite Bio Presents Preclinical Data Supporting GPH101 in Sickle Cell Disease at 49th Annual Sickle Cell Disease Association of America National Convention source


$OTLK +0.9% Outlook Therapeutics’ Positive NORSE THREE Safety Data Presented at 2021 American Society of Retina Specialists for ONS-5010 Ophthalmic Bevacizumab source


$HZNP 0.0% New TEPEZZA® (teprotumumab-trbw) Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting source


$VLDN +2.0% Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements source


$ALBO +0.6% Albireo Announces Exclusive Licensing Agreement with Jadeite Medicines for Bylvay™ (odevixibat) in Japan source


$BBIO 0.0% bridgebio pharma announces progress in its kras portfolio, new gene therapy programs, and updates on advancements across its r&d pipeline targeting genetic diseases and cancers source


$OTIC 0.0% Otonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313 source


$NTLA +1.7% Intellia Therapeutics to Present New Preclinical Data Highlighting In Vivo and Ex Vivo Genome Editing Advances at 2021 European Society of Gene & Cell Therapy Annual Congress source


$VTVT +5.0% vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes source


$TARA +11.9% Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer source


$RDHL +1.3% RedHill Biopharma Announces New U.S. Patent Covering Talicia for H. pylori Infection Through 2034 source


$DCPH +6.8% Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor source


$NXRP +61.1% NRx Pharmaceuticals Announces Progress on Worldwide Commercial Scale Development of ZYESAMI™ (aviptadil) source


$AERI +1.8% Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan source


Financial & Business Updates

$SRPT +4.1% Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock source


$BYCY +1.5% Bicycle Therapeutics Announces Proposed $125,000,000 Public Offering of American Depositary Shares source


$EVFM +0.7% Evofem Biosciences Announces $10 Million Registered Direct Offering of Series B Preferred Stock source

 

Posted by FS/JM

0 comments
bottom of page